The story of Viagra and its impact on the pharmaceutical sector presents a intricate question regarding its continued appeal as an investment. Initially a blockbuster success, generating vast revenues, generic competition has significantly eroded financial returns. While major pharmaceutical firms continue patents on related therapies and develop n

The trajectory of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's unprecedented popularity, generated substantial wealth , the expiry in key markets has introduced substantial volatility. Investors are now grappling with the impact of rival medications , di